title: Luteolin and its inhibitory effect on tumor growth in systemic malignancies.
abstract: Lamy et al have provided interesting data in their recent article in your esteemed journal. Luteolin augments apoptosis in a number of systemic malignancies. Luteolin reduces tumor growth in breast carcinomas. Luteolin mediates this effect by up-regulating the expression of Bax and down-regulating the expression of Bcl-xL. EGFR-induced MAPK activation is also attenuated. As a result there is increased G2/ M phase arrest. These effects have been seen both in vivo as well as in vitro. It also reduces ERα expression and causes inhibition of IGF-1 mediated PI3K-Akt pathway. Luteolin also activates p38 resulting in nuclear translocation of the apoptosis-inducing factor. Simultaneously it also activates ERK. As a result there is increased intra-tumoral apoptosis which is caspase dependent as well as caspase independent.
authors: 74 crossing place, Mechanicsville, VA, USA. shailendrakapoor@yahoo.com
authors: Shailendra
authors: S
authors: Kapoor
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D059808:Polyphenols / Q000494:pharmacology*; D050796:STAT3 Transcription Factor / Q000378:metabolism*
chemical_list: D020533:Angiogenesis Inhibitors; D015850:Interleukin-6; D059808:Polyphenols; D050796:STAT3 Transcription Factor